Background: A comprehensive review was made of the literature on the health-related quality of life (HRQL) and economic outcomes of children with acute lymphoblastic leukemia (ALL), the most common of all cancers in childhood. Objectives: The primary objectives of the review were to locate and describe measures of HRQL used in pediatrics and in pediatric oncology that might be applicable to ALL, to summarize studies that have applied HRQL measures to ALL, to identify and summarize economic evaluations of the costs and consequences of care for pediatric ALL, and to identify areas requiring further research. Data sources: To identify the HRQL literature in pediatric ALL, searches were run on the major biomedical and social science bibliographic databases. Search terms included a variety of MeSH and other thesaurus terms, text words, names of HRQL instruments, and the names of key authors in the field. The economic literature searches included most of the same databases, with the addition of the National Health Service Economic Evaluation Database and EconLit. Searches on specific authors and instruments and hand searches were also conducted. Study selection: Only English language studies published from 1975 through 2000 were included. Data extraction: Standardized data extraction forms were used to abstract information from HRQL and economic evaluation studies. Two reviewers independently screened the search results, and differences were resolved by consensus. Data synthesis: A number of generic HRQL measures, both adult and pediatric, have been applied in pediatric ALL. In addition, a number of pediatric oncology-specific instruments and pediatric oncology disease-specific instruments have been developed. Most of these instruments have been used to measure the health status of patients undergoing therapy. Despite the limited numbers of patients and resources available to assess HRQL measures in children with cancer, a fairly substantial body of literature has been published. Economic studies of pediatric ALL have only recently been undertaken. Most studies focus on a particular, narrow aspect of costs associated with the disease. There are relatively few cost-effectiveness studies that compare the costs and consequences of two or more treatment options. There are no published, comprehensive economic evaluations of pediatric ALL. Conclusions: HRQL measures provide not only important information on the improvements offered by new therapies but also an outcome measure for economic evaluations. Recently developed HRQL measures and applications that include the direct assessments of children are important contributions. By the age of 7 or 8 years, children can generally provide reliable responses. Furthermore, children often provide information that is not available from parental reports (e.g., in the more subjective areas of pain and emotion). However, the use of multiple viewpoints, such as the patient, parent, and health professional perspectives, can provide 
BACKGROUND
Acute lymphoblastic leukemia is the most common of all childhood cancers. Survival rates have improved dramatically over the latter course of the 20 th century for most forms of childhood cancers, including ALL. The overall survival rate for children with acute lymphocytic leukemia (ALL accounts for the vast majority of cases in that category) in the United States has improved from 53.8% in 1974-1976 to 86.8% for the period 1992-1997 (3) .
The tremendous progress in cure rates is attributable, in part, to the cooperative trial program among centers of excellence in pediatric cancer (4) . Children who receive treatment according to well-defined protocols in specialized children's centers have improved survival when compared with that of children who received treatment outside these centers for ALL, lymphoma, Wilms tumor, medulloblastoma, rhabdomyosarcoma, and Ewing's sarcoma (4) . Now that the majority of pediatric patients survive their cancer, quality-of-life measurement is increasingly recognized as an important method of evaluating the impact of treatment interventions and understanding the shortand long-term morbidity (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) . The two key issues are the burden of morbidity during the treatment process and the longterm effects of the disease and its treatment on the health status and health-related quality of life (HRQL) of childhood cancer survivors (16) . Given the current focus of many pediatric oncology trials on toxicity and sequelae-sparing therapies, the assessment of HRQL is becoming increasingly important.
A substantial literature has accumulated on the measurement of HRQL in cancer; however, until recently, relatively little of this research focused on pediatric oncology. Health status and HRQL instruments have been developed specifically for use in cancer patients, such as the Functional Living Index-Cancer (FLIC) (17) and the Functional Assessment of Cancer Therapy (FACT) (18) , but these instruments do not consider HRQL issues in the context of pediatric oncology.
As for any HRQL measure, an instrument for use in pediatric cancer should possess evidence of content/construct validity and reliability in the patient population of interest. One of the challenges in the development of childhood cancer-specific HRQL measures is to identify the primary HRQL domains of importance. The domains of importance may differ according to the type of cancer and the treatment regimens used. Although many survivors of cancer in childhood enjoy normal health, chronically poor health and specific deficits in cognitive and emotional status have been identified in some children who have had cancer (14) . Other aspects of HRQL are cancer-specific concerns such as alopecia, mucositis, and gonadal damage leading to infertility. In some cases, patients experience acute reversible toxic effects; in other cases, the toxic effects persist or are irreversible. The assessment of HRQL provides a mechanism to measure and analyze these complex issues.
Further to the challenge of developing valid and reliable HRQL measures for use in pediatric cancer is the fact that the cognitive capacity of children for self-evaluation changes with the normal process of maturation (16, 19) . Thus, measures that deal with the problems specific to HRQL measurement in children by age group are needed. Longitudinal assessments of HRQL are complicated by the developmental stages that pediatric subjects undergo during treatment and follow-up (8) . Proxy respondents are frequently used, and an understanding of the relationship between parent and child/adolescent assessment of HRQL is important.
One of the first scales developed specifically for use in children with cancer was the Play Performance Scale for Children (PPSC) (20) , designed as a measure of a child's ability to perform day-to-day activities as an indication of health status (20) . Since the emergence of the PPSC, a number of generic and cancerspecific HRQL measures have been developed. Trudel et al. (21) identified the following quality-of-life measures available for pediatric cancer patients: the PPSC (20) , the Quality of WellBeing Scale (QWB) (22) , the Perceived Illness Experience (PIE) Scale (23) , the Pediatric Oncology Quality of Life Scale (POQOLS) (24) , and the Health Utilities Index (HUI) Mark 2 system (25) .
This review includes the following three types of published studies (available up to April 2001): 1) HRQL measures that potentially could be used in pediatric cancer, 2) studies that have applied HRQL measures in populations that include children with ALL, and 3) economic studies involving treatments for children with ALL. The first objective of this review was to identify and describe generic, specific, and disease-specific HRQL measures developed or applied in childhood ALL. The second objective was to identify and describe economic evaluation studies dealing with pediatric ALL.
METHODS

Literature Search
HRQL and health status in pediatric ALL. Literature searches were run on several databases by using various search strategies as shown below. More than 1800 references were identified. A review of the titles and abstracts revealed that most studies were not specific to HRQL in children with leukemia. For example, many studies focused on the quality of life of the parents and on the neurological/cognitive impacts of cancer therapies on adult survivors of leukemia in childhood. The search was restricted to studies published since 1975. Only studies published in English were selected for review. An appendix providing details on the search strategies, keywords, and databases consulted is available from the authors. Search strategies will be described briefly here. Standard databases including PubMed (MEDLINE), EMBASE, Web of Science, and CancerLit were consulted. Given previous knowledge of important studies and measures, specific searches for papers by the authors or for particular HRQL measures were also conducted. Key journal supplements and relevant sources from the personal collection of one of the authors (D. H. Feeny) were also used.
Economic evaluations and costing studies. For the economic component of the review, literature searches were run on biomedical databases used in the HRQL searches and also on economic literature databases, such as EconLit and the National Health Service Economic Evaluation Database. (More details on the search strategies are recorded in an appendix, available upon request.) More than 250 references were identified. However, upon examination of the abstracts, most were not specifically relevant to the costs of ALL in children. This review was also restricted to English language studies published since 1975.
Data Extraction and Presentation
Citations identified by the literature search were independently screened by two reviewers (A. S. Pickard and L.-A. Topfer). Papers that appeared to be relevant were retrieved and were included or rejected on the basis of a review of the entire paper. Disagreements were resolved by consensus. Information was abstracted from each study by using standardized data collection forms (see "Appendix 1"). Three data collection forms were developed, and the information from these forms is summarized in Tables 1-3. Form I was structured to describe HRQL instruments that have been used or may find application in pediatric ALL in North America in terms of the following: domains (dimensions of health status) included on each measure, intended respondent and age group, number of items, application format, country of origin, and availability of translations in other languages.
Form II was used to extract evidence from studies that have applied HRQL instruments to pediatric ALL. This form included aspects such as the following: sample characteristics, data collection, respondents, study design, phase of care, medication regimen, and additional evidence on the measurement properties of each HRQL instrument generated by the study. This information is summarized in Table 2 , which reports the actual activity or applications of the HRQL measures identified as having potential for application in Table 1 .
A taxonomy of HRQL measures and explanations of psychometric properties and issues related to HRQL measurement are available elsewhere (16, 26, 27) . Evidence on reliability and validity reported in Table 2 pertains only to studies involving one or more children with ALL. The characteristics in column 13 of Table 2 (i.e., confidence intervals and power calculations) were added in a recent update for this article and were not available (had not been abstracted) for studies identified in an earlier phase of this project. Only results related to the HRQL measure of interest are reported in Table 2 . A number of studies aggregated ALL patients with other types of cancer patients and did not report disaggregated results based on type of cancer. The same patient cohort may have been studied in more than one paper. Papers that explored single domains of HRQL, such as anxiety, were excluded. Studies investigating the late effects of childhood cancer on the HRQL of adults were also excluded.
Form III was used for the economic evaluation and costing studies. The results from economic evaluations and costing studies on patient samples or subsamples that include children with ALL (Table 3) are reported on the basis of criteria that constitute guidelines for the performance of economic evaluations in health care (28, 29) . Our tables are intended to convey a brief summary of the contents of each study or instrument and are not a substitute for reading the papers.
RESULTS
The HRQL measures were subdivided into health profiles, preference-based measures, and childhood cancer-specific pediatric HRQL instruments (Table 1) . A number of pediatric oncology-specific instruments have been developed, such as the Miami Pediatric Quality of Life Questionnaire, the Pediatric Cancer Quality of Life Inventory (PCQL-32), and the POQOLS. Finally, several pediatric oncology disease-specific instruments have been developed. For instance, the Disease Specific Impairment Inventories-Bone Marrow Transplantation (DSII-BMT) focuses on HRQL in patients undergoing bone marrow transplantation. These instruments have been used in studies of several childhood cancers, including ALL. No HRQL measure specific to ALL was identified.
A number of generic HRQL measures (e.g., the QWB and the HUI Mark 2 [HUI2] and Mark 3 [HUI3] systems) and generic pediatric HRQL measures (e.g., the Child Health Questionnaire [CHQ] ) have been applied in pediatric ALL (Table 2 ). These instruments have been used both to assess health status and HRQL during treatment and to assess outcomes.
Most of the literature on the cancer-specific pediatric measures focused on evidence of validity and reliability. Studies that describe a specific treatment regimen were more likely to have a primary objective of evaluation of therapy, with information on the psychometric properties more likely to have been a secondary objective.
Sawyer et al. (30) provided evidence on interrater agreement (generally moderate to high but seldom perfect) for the CHQ (Table 2 ). This study also provides similar evidence for functional status measures. Comparable results for interrater reliability are reported by Parsons et al. (31) for the Child Health Rating Inventories (Table 2) . Evidence on interrater reliability is also reported by Barr et al. (32) . Test-retest results for HUI2 are reported by Trudel et al. (21) .
Internal consistency results for the QWB are reported by Bradlyn et al. (22) . Phipps et al. (33) reported estimates of internal consistency for the Behavioral, Affective, and Somatic Experiences Scale (BASES) ( Table 2) . Eiser et al. (23) reported results on internal consistency and test-retest reliability (Table  2) . Varni et al. (34, 35) reported on internal consistency and interrater reliability for the PCQL-32 (Table 2) . Goodwin et al. (24) reported high levels of internal consistency and interrater reliability for POQOLS (Table 2 ). In general, internal consistency and test-retest reliability have been acceptable for most instruments.
There are a number of areas of application for cancer outcome measures. These include the following categories: 1) studies to provide evidence on the efficacy or effectiveness of an intervention, 2) studies to provide evidence on the costeffectiveness of an intervention, 3) studies to describe the patterns of care, 4) studies to monitor or measure quality of care, and 5) cost of illness studies. With respect to the HRQL literature on pediatric ALL summarized in Table 2 , approximately 9.4% of the studies fell into category 1 (establish effectiveness), 46 .9% fell into category 3 (patterns of care), and 43.8% fell into category 4 (monitor quality of care). Most of the latter group were late-effects studies that have played an important role in documenting the sequelae of therapy and disease in childhood cancer. Results from late-effects studies have been important in generating interest in new treatments that are toxicity and sequelae sparing.
Generic profile measures, such as the CHQ, and generic preference-based measures, such as the HUI, have been applied in a number of late-effects studies that monitor the quality of care in terms of the health status and HRQL in a cohort of survivors. The use of broad comprehensive measures to examine late effects is appropriate.
Many of the studies of HRQL in pediatric ALL have been done in the context of assessing late effects: the quality of survivorship. The overwhelming majority of these studies are crosssectional. These studies have provided important evidence on construct validity (and in some cases internal consistency reliability); however, given their cross-sectional nature, they have not provided information on responsiveness or sensitivity to change.
In pediatric ALL, there are a number of standard phases of treatment specified within widely used treatment protocols. These phases typically involve diagnosis, induction of remission, consolidation of remission, maintenance therapy, and discharge to long-term follow-up. In less successful cases, additional phases, such as reinduction of remission, intensification of therapy, salvage therapy, or palliative care, may be relevant. The bulk of available evidence on HRQL is related to the quality of survivorship. Speechley et al. (36) provided evidence on the construct validity of the CHQ and HUI2 (Table 2 ). Both measure captured burdens expected on the basis of known groups. Correlations among similar constructs included in both measures were moderate to high. Barr et al. (37) provided evidence on the construct validity of HUI2 ( Table 2 ). The burden of morbidity among survivors of high-risk ALL exceeded that among survivors of standard-risk ALL. Feeny et al. (38) provided evidence on the construct validity of HUI2 in a cohort of survivors of high-risk ALL. Burdens were found in cognition and emotion. Bradlyn et al. (22) found that QWB scores and performance status ratings were significantly correlated. Trudel et al. (21) reported on results of expected correlations between POQOLS and HUI2.
There is less evidence on the responsiveness (sensitivity to change) of these generic instruments to monitor changes over time during therapy. In some cases these generic measures have been responsive. For instance, Barr et al. (32) and Furlong et al. (39) provided evidence on the responsiveness of HUI2 and No *BMT ‫ס‬ bone marrow transplantation; DRGs ‫ס‬ diagnosis-related groups; G-CSF ‫ס‬ granulocyte colony-stimulating factor; GM-CSF ‫ס‬ granulocyte-macrophage colony-stimulating factor; HCO ‫ס‬ Home Care Organization; N/A ‫ס‬ not available; NEJM ‫ס‬ New England Journal of Medicine; PBPC ‫ס‬ peripheral blood progenitor cell; PBPCT ‫ס‬ peripheral blood progenitor cell transplantation; RCT ‫ס‬ randomized controlled clinical trial; rhGM-CSF ‫ס‬ recombinant human GM-CSF; SD ‫ס‬ standard deviation; TBI ‫ס‬ total-body irradiation; TC ‫ס‬ teizoplanin plus ceftriaxone; TPN ‫ס‬ total parental nutrition; UHC ‫ס‬ University Hospital Consortium.
HUI3 in detecting changes in HRQL during 3-week cycles of high-dose corticosteroids during "maintenance" therapy for ALL ( Table 2) . As predicted a priori, patients experienced difficulties with mobility/ambulation, pain, and emotion during the week that they were on high-dose corticosteroids and demonstrated few problems during the week off all therapy. Nonetheless, given the coarseness of the generic measures, there is reason to suspect that these measures may not capture all of the important HRQL trends experienced during therapy. The complementary use of specific, targeted measures is therefore desirable. Kazak et al. (40) provided evidence on the responsiveness of the POQOLS. Statistically significant changes in POQOLS scores were detected over time in the context of a randomized controlled clinical trial. Within the context of a prospective study, Parsons et al. (31) provided evidence of responsiveness for the Child Health Rating Inventories.
Studies involving the costing of health care services in pediatric ALL have started to emerge only recently (Table 3 ). There are a number of narrowly focused studies reporting on estimates of the cost of particular components of treatment, such as the cost of treating febrile neutropenia or using granulocyte colonystimulating factor. For instance, Charnas et al. (41) examined alternatives for the treatment of febrile neutropenia in children with cancer. Luce et al. (42) retrospectively analyzed data from a randomized controlled clinical trial of patients undergoing bone marrow transplantation. The mean charges were lower for patients receiving recombinant human granulocyte-macrophage colony-stimulating factor than for those receiving placebo. The availability of these studies may well reflect sponsorship by pharmaceutical firms. There are relatively few cost-effectiveness studies in which the costs and consequences of two (or more) relevant treatment options (e.g., inpatient versus home care) are compared. Only one study focuses on costs borne by families (43) . There are no published, comprehensive economic analyses of pediatric ALL.
With respect to the areas of application, approximately 73.1% of the economic studies listed in Table 3 focus on establishing cost-effectiveness, whereas 26.9% provide descriptive evidence on the cost of illness.
During the 1990s, there was a trend toward an increase in the annual number of publications (Fig. 1) . Few HRQL or costing studies in ALL were published prior to 1990. Although numerous generic and pediatric cancer-specific measures were identified that could potentially be used to study pediatric ALL, most have only been applied in a handful of studies (Table 4) . Among the generic measures, the HUI2 and HUI3 were the most widely applied. Overall, the POQOLS (24) pediatric cancer-specific HRQL measure was the most widely used instrument in studies including children with ALL.
DISCUSSION
Historically, HRQL measures have not often been used to supplement traditional end points of treatment effectiveness in pediatric oncology (8) . HRQL measurement in pediatric oncology is particularly challenging. The development of measures requires access to a sufficient number of patients (and families). Adequate instrument development requires the accumulation of evidence on the measurement properties of instruments. Relevant properties include test-retest reliability, interrater reliability, sensitivity to change (or responsiveness), and validity. Given the absence of a "gold standard" for assessing HRQL, the investigation of validity is largely accomplished through construct validation. Although commentators tend to declare that instruments have been shown to be reliable and valid, in reality such evidence tends to be context specific (27) . In particular, construct validity involves the accumulation of evidence over time.
Given that the incidence of pediatric ALL, the most common of all cancers in childhood, is (fortunately) low and that even large tertiary care centers typically have at most only a modest number of patients, the extent of evidence on HRQL in pediatric ALL gathered during the 1990s is impressive. It is also remarkable that investigators have been able to develop a number of promising measures. In general, the pediatric oncology-specific and pediatric oncology disease-specific instruments focus on health status and HRQL during therapy. Thus, it may be wise to use these measures along with generic measures that are also relevant for the assessment of long-term outcomes. Despite the limited patient numbers and resources available, there has been substantial progress on HRQL assessment in childhood cancer.
To date, investigators from a wide variety of disciplines have contributed to the development of HRQL measures for use in pediatric oncology. The disciplines included pediatric oncology, epidemiology, economics, decision science, psychology, healthservices research, nursing, and statistics. Experience in instrument development in pediatric oncology is consistent with experience in adult HRQL in which three major measurement traditions are represented: psychometrics, clinimetrics, and economics. Although the involvement of a number of disciplines may raise the cost of studies, it has enriched the variety and quality of the measures developed. In general, it is important to involve a range of disciplines in work on HRQL in pediatric oncology.
Toward the objective of enriching the evidence on HRQL measurement in pediatric oncology, several themes emerge from this review. [These themes build upon earlier publications by Feeny et al. (16, 44) .]
Theme 1: HRQL Tools Address Important Questions
Survival rates for most cancers in childhood have risen dramatically over the last five decades. Pediatric ALL was almost universally fatal in the early 1940s; today the survival rate is greater than 85%. An important reaction among clinical researchers has been a shift in focus to finding therapies that lessen the toxicity burden during treatment and reduce sequelae, without sacrificing survival. HRQL measures provide crucial information on whether or not the new therapies really are toxicity and sequelae sparing. HRQL tools provide a solid evidential basis for assessing quality-adjusted survival and can serve as inputs into economic evaluations. Greater use needs to be made of the measures that have been developed, especially in longitudinal studies. Surrogate clinical measures are often incomplete and can be misleading. The formal assessment of HRQL during treatment and the assessment of the HRQL associated with longterm outcomes are essential in answering many of the key clinical questions.
Theme 2: Measures Are Available
As this review demonstrates, there are a number of generic and specific measures that have been used productively in pediatric ALL. There is substantial evidence on the reliability, responsiveness, and validity of some measures; in other cases, the evidence is still emerging. Twenty years ago an investigator interested in assessing HRQL in pediatric ALL would have had little choice of measures. Today there are a number of measures from which to choose; the availability of useful measures is no longer a barrier. Efforts focused on accelerating the accumulation of evidence are needed (see theme 5 below); nonetheless, suitable measures already exist. The lack of availability of a credible instrument is seldom a valid reason for not measuring HRQL in pediatric ALL studies.
Theme 3: Children Can Respond on Their Own Behalf
Early studies on HRQL in pediatric ALL tended to rely on reports by parents and health care professionals. More recently in pediatric studies in general and pediatric ALL in particular, a number of studies have also asked children to complete questionnaires. In general, results indicate that by the age of 7 or 8 years, children generally provide reliable responses. Furthermore, a number of studies [e.g., Parsons et al. (31) ] indicate that children can often provide information that is unavailable from parental reports. Thus, children should be engaged as respondents whenever possible.
Theme 4: There Are Multiple Valid Viewpoints
Information provided by patients, parents, and healthcare professionals is often complementary. Each type of respondent has a valid and important perspective. Children can provide insights on their HRQL, particularly the intrinsically subjective elements such as pain and emotion. Parents observe their children in a variety of contexts and social settings, and their responses can incorporate that information. Healthcare professionals are often more aware of the full range of experiences and are well informed about norms both for children with pediatric ALL and for the general pediatric population. Information from each of these three types of respondents is potentially valuable. Thus, rather than rely on only one source of information, it is important to develop strategies to share information. Furthermore, evidence on interrater reliability (or agreement) indicates that, in general, the responses of children, parents, and health care professionals are not interchangeable. This is especially germane for subjective dimensions (domains) of health status.
Theme 5: Implications-Harness the Cooperative Groups
The overwhelming majority of children with ALL in the United States and Canada are treated on established protocols for which there is rigorous evidence of clinical effectiveness based on results from randomized controlled clinical trials (4). Many children being treated for ALL are enrolled in clinical trials and related studies. This pediatric experience (which, in general, contrasts with the situation in adult oncology) is a reflection of the considerable accomplishments of the two major cooperative groups: the Pediatric Oncology Group and the Childhood Cancer Study Group. Recently, these two groups have merged into the Children's Oncology Group (COG). The use of the cooperative group will help to overcome the limited sample sizes available at even the largest treatment centers. It is now time to add HRQL to the scope of activities of the cooperative group. First, modest funds should be made available for methodological assessments of HRQL measures. Second, expertise on HRQL measurement (including specific, generic, and preference-based measures) should be added to at least some of the teams that design future trials. Third, the cooperative group needs to start to include existing measures in their studies. In particular, there are no examples in the published literature of studies using HRQL throughout the process of treatment from diagnosis and induction of remission, to discharge and to longterm follow-up. More information on the natural history of HRQL during all phases of treatment and survival is needed. Currently, we have a number of useful snapshots of portions of that experience, but we lack comprehensive longitudinal evidence. Given the recent inclusion of HRQL measures in a few trials, preliminary evidence on the patterns of HRQL over time will be emerging soon. Fourth, when the assessment of existing tools or experience in studies identifies a major gap, the cooperative group could be used to expedite the development of new instruments to ameliorate those gaps. Of course, the inclusion of HRQL measures in any study must be linked explicitly to specific study objectives or hypotheses to be tested.
If the methodological work on HRQL in pediatric oncology and the application of existing HRQL measures in the COG trials become reasonably common, if not routine, the rate of progress on HRQL in pediatric oncology will be increased substantially. The spectrum of morbidities in many other illnesses of children is encompassed by the morbidities among children with cancer (16) . Therefore, a focus on HRQL in pediatric oncology affords a context within which to build a prototype strategy for the assessment of HRQL among all children. In fact, several approaches originally developed in the context of childhood cancer have been applied already in other areas in pediatrics, such as the use of the HUI in follow-up studies among survivors of extremely low birth weight and population health surveys of children. HRQL studies in pediatric oncology can serve as a foundation for HRQL studies in other areas of pediatrics. Tools developed in pediatric HRQL may be directly transferable to other areas or may serve as a useful starting point for the development of other specific pediatric HRQL instruments.
Theme 6: Implications-Identification of Topics for the Research Agenda
The accumulation of additional evidence on the existing measures is a key item for the research agenda. The generation of such evidence will help investigators to learn which measures are suitable for which purposes and how to interpret HRQL scores. Evidence on the lack of adequate measures in particular situations will help to identify priorities for the development of new measures. Only by subjecting existing instruments to appropriate assessments will we know if new measures need to be developed. In particular, additional evidence on responsiveness is needed. In addition, evidence on the entire path of HRQL experience from diagnosis through adulthood is needed.
The measures that have been used to date have primarily been used for discriminative (distinguish among persons or groups at a point in time; cross-sectional study) or evaluative (assessment of within-person change or time; prospective studies such as clinical trials) purposes. Another set of issues for the research agenda concerns the use of these measures in managing individual patients and their families. Can HRQL scores be used to identify patients with elevated treatment morbidity for whom additional interventions may be indicated? Can simple HRQL measures be used as screening tools to identify subjects for more extensive evaluation?
A related issue that has received little attention is the prognostic value of baseline observations of health status and HRQL. In a number of (but not all) areas in adult oncology, baseline HRQL measures have been shown to have independent prognostic value for survival, controlling for standard clinical prognostic indicators [see for instance Clinch (17) , Coates et al. (45) , Dancey et al. (46) , and Ganz et al. (47) ]. It will be interesting to see if the HRQL measures have predictive value in pediatric oncology settings.
Most work to date involving self-report by children has been in school-aged children, yet many of the children with ALL are preschoolers. A number of investigators are exploring innovative approaches to obtaining HRQL information from younger children; such approaches include cartoon and touch-screen computer formats. Clearly, additional work on developing and assessing these and other approaches is needed. In general, HRQL measures for children need to make allowances for the development stages of childhood; this will be particularly important for measures that are used for preschool children.
Finally, the accumulation of evidence on interpretability and usefulness of HRQL in pediatric oncology are important research priorities (16, (48) (49) (50) . Interpretability refers to the extent to which one can assign meaning, both qualitatively and quantitatively, to HRQL scores (51) . Usefulness refers to the impact that assessing HRQL has on decisions that are made, including the management of specific patients and families, the development of clinical policy and guidelines, the conduct of clinical trials, resource allocation, and the identification of research priorities. There is relatively little evidence on interpretability in the context of pediatric oncology and even less on usefulness. These gaps should be filled.
In summary, HRQL measures have the potential to assist in the identification of the morbidity burdens of treatment, assessment of the quality of survival, evaluation of new treatments and interventions in pediatric oncology, and the management of patients and families. There is a small but impressive collection of measures with proven track records. A variety of disciplines have contributed to the existing body of knowledge. The instruments and expertise to support vigorous application of HRQL tools to clinically important questions in cancer care in pediatric settings exist. Investments in the application of these tools will likely pay handsome returns. 
